JP2002502354A - 分子を同定又は単離する方法及びそれによって同定された分子 - Google Patents
分子を同定又は単離する方法及びそれによって同定された分子Info
- Publication number
- JP2002502354A JP2002502354A JP50197297A JP50197297A JP2002502354A JP 2002502354 A JP2002502354 A JP 2002502354A JP 50197297 A JP50197297 A JP 50197297A JP 50197297 A JP50197297 A JP 50197297A JP 2002502354 A JP2002502354 A JP 2002502354A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sample
- nucleic acid
- vector
- transfected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. HLA−A2.1分子に結合し、次の配列、 Xaa Leu Xaa7を有する単離ノナペプチドであって、 第6番目のアミノ酸残基が、Ser,Lys又はPheであり、第9番目のア ミノ酸残基がVal又はIleである単離ノナペプチド。 2. 配列番号7、 配列番号8、および 配列番号9、 からなるグループから選択される単離ノナペプチド。 3. 配列番号7である請求項1の単離ノナペプチド。 4. 配列番号8である請求項1の単離ノナペプチド。 5. 配列番号9である請求項1の単離ノナペプチド。 6. 配列番号1の核酸分子によってコードされる単離タンパク質。 7. 腫瘍関連タンパク質の存在の可能性をスクリーニングする方法であって、 サンプルと、配列番号4および配列番号5のうち少なくとも一つと接触させ、そ して前記サンプル中における前記腫瘍関連抗原の判定として、標的に対する配列 番号4又は配列番号5のハイブリダイゼーションを判定することからなる方法。 8. 前記サンプルと、配列番号4および配列番号5の両方とを接触させる、請 求項7の方法。 9. ポリメラーゼ連鎖反応工程を有する、請求項8の方法。 10.患者によって生産される免疫反応性物質を判定する方法であって、以下の 工程、 (a)前記患者から得た細胞のcDNAライブラリーを作成する工程、 (b)前記cDNAライブラリーをベクターに挿入する工程、 (c)前記ベクターを宿主細胞中にトランスフェクションして、トランスフェ クションされた宿主細胞を作る工程、 (d)前記トランスフェクションされた宿主細胞を培養して前記免疫反応性物 質を発現させる工程、 (e)前記トランスフェクションされた宿主細胞を溶解して溶解物を形成する 工程、 (f)前記免疫反応性物質に対する免疫性結合パートナーを含有するサンプル を、溶解させた、トランスフェクションされていない宿主細胞のサンプルと接触 させて、前記トランスフェクションされていない宿主細胞に対して特異的なすべ ての免疫性結合パートナーを、前記サンプルから除去して、除去処理を施したサ ンプルを作る工程、 (g)前記除去処理を施したサンプルを、前記cDNAが挿入されたものと同 じであって、かつ、いずれのcDNAも有さないベクターでトランスフェクショ ンされた溶解させた宿主細胞のサンプルと接触させて、前記ベクターに対して特 異的なすべての免疫反応性結合パートナーを除去し、これによって2回除去処理 を施したサンプルを作る工程、 (h)前記2回除去処理を施したサンプルを、前記工程(f)の溶解物と接触 させ、これによって、前記免疫反応性結合パートナーに対して特異的なすべての 免疫反応性結合パートナーがそれに結合する工程、そして (i)前記工程(h)に於ける結合を判定し、前記免疫反応性物質を判定する 工程、 からなる方法。 11.更に、前記免疫反応性物質を発現した前記トランスフェクションされた宿 主 細胞を同定し、そこに含まれる前記cDNAを単離する工程を有する請求項10 の方法。 12.更に、すべての免疫反応性結合パートナーを除去し、前記物質に対して特 異的な一つの免疫反応性結合パートナーを単離する工程を有する請求項10の方 法。 13.前記宿主細胞が大腸菌である請求項10の方法。 14.前記ベクターが、ウィルスベクターである請求項10の方法。 15.前記ウィルスベクターが、真核細胞性ウィルスベースのベクターである請 求項14の方法。 16.前記ウィルスベクターが、ファージベクターである請求項14の方法。 17.前記ファージが、ラムダファージである請求項16の方法。 18.前記宿主細胞が、原核細胞である請求項10の方法。 19.前記宿主細胞が、真核細胞である請求項10の方法。 20.更に、前記2回除去処理を施したサンプルとの接触の前に、前記溶解物を 固相に固定化する工程を有する請求項10の方法。 21.前記サンプルが血清である請求項10の方法。 22.前記血清が自己由来血清である請求項21の方法。 23.前記免疫性結合パートナーが抗体である請求項10の方法。 24.前記免疫反応性物質がガンに関連する抗原である請求項10の方法。 25.前記免疫反応性物質が自己免疫関連抗原である請求項10の方法。 26.前記免疫反応性物質が病原体によって生産されたものである請求項10の 方法。 27.その相補的配列が、ストリンジェントな条件下で配列番号1にハイブリダ イズする、腎細胞ガン−特異的抗原をコードする単離核酸分子。 28.その相補的配列が、ストリンジェントな条件下で配列番号2にハイブリダ イズする、ホジキン病−特異的抗原をコードする単離核酸分子。 29.その相補的配列が、ストリンジェントな条件下で配列番号3にハイブリダ イズする、メラノーマー特異的抗原をコードする単離核酸分子。 30.配列番号1から成る請求項27の単離核酸分子。 31.配列番号2から成る請求項28の単離核酸分子。 32.配列番号3から成る請求項29の単離核酸分子。 33.プロモーターに操作可能にリンクされた請求項27の単離核酸分子を有す る発現ベクター。 34.プロモーターに操作可能にリンクされた請求項28の単離核酸分子を有す る発現ベクター。 35.プロモーターに操作可能にリンクされた請求項29の単離核酸分子を有す る発現ベクター。 36.請求項27の単離核酸分子でトランスフォーメーション又はトランスフェ クションされた細胞ライン。 37.請求項28の単離核酸分子でトランスフォーメーション又はトランスフェ クションされた細胞ライン。 38.請求項29の単離核酸分子でトランスフォーメーション又はトランスフェ クションされた細胞ライン。 39.請求項33の発現ベクターでトランスフォーメーション又はトランスフェ クションされた細胞ライン。 40.請求項34の発現ベクターでトランスフォーメーション又はトランスフェ クションされた細胞ライン。 41.請求項35の発現ベクターでトランスフォーメーション又はトランスフェ クションされた細胞ライン。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/479,328 | 1995-06-07 | ||
US08/479,328 US5698396A (en) | 1995-06-07 | 1995-06-07 | Method for identifying auto-immunoreactive substances from a subject |
US08/580,980 | 1996-01-03 | ||
US08/580,980 US6025191A (en) | 1995-06-07 | 1996-01-03 | Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof |
US08/644,116 US6140464A (en) | 1995-06-07 | 1996-05-10 | Nonapeptides that bind a HLA-A2.1 molecule |
US08/644,116 | 1996-05-10 | ||
PCT/US1996/009726 WO1996040209A1 (en) | 1995-06-07 | 1996-06-07 | Method for identifying or isolating a molecule and molecules identified thereby |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002502354A true JP2002502354A (ja) | 2002-01-22 |
Family
ID=23903564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50197297A Ceased JP2002502354A (ja) | 1995-06-07 | 1996-06-07 | 分子を同定又は単離する方法及びそれによって同定された分子 |
Country Status (11)
Country | Link |
---|---|
US (2) | US5698396A (ja) |
EP (1) | EP0831879B1 (ja) |
JP (1) | JP2002502354A (ja) |
CN (1) | CN1136914C (ja) |
AT (2) | ATE235248T1 (ja) |
CA (1) | CA2223566C (ja) |
DE (2) | DE69627056T2 (ja) |
DK (1) | DK0831879T3 (ja) |
ES (1) | ES2180782T3 (ja) |
PT (1) | PT831879E (ja) |
WO (1) | WO1996040209A1 (ja) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589579A (en) * | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
US20010053523A1 (en) * | 1995-06-02 | 2001-12-20 | M&E Biotech A/S. | Method for identification of biologically active peptides and nucleic acids |
US6365344B1 (en) * | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
JP2000504220A (ja) | 1996-01-23 | 2000-04-11 | ライガル ファーマシューティカルズ インコーポレイテッド | トランス支配性細胞内作用因子ペプチドおよびrna分子のスクリーニング方法 |
US6027916A (en) | 1996-10-09 | 2000-02-22 | Human Genome Sciences, Inc. | Galectin 9 and 10SV Polynucleotides |
US6287756B1 (en) * | 1997-05-05 | 2001-09-11 | Ludwig Institute For Cancer Research | Methods for determining presence of cancer in a sample by determining expression of an SSX gene |
US6548064B1 (en) * | 1997-05-05 | 2003-04-15 | Ludwig Institute For Cancer Research | Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6043084A (en) * | 1997-10-10 | 2000-03-28 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer |
US6403373B1 (en) | 1997-10-10 | 2002-06-11 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these |
US6218521B1 (en) | 1997-07-17 | 2001-04-17 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules associated with gastric cancer and methods for diagnosing and treating gastric cancer |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US6140050A (en) * | 1998-06-26 | 2000-10-31 | Ludwig Institute For Cancer Research | Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith |
US6440663B1 (en) | 1998-10-05 | 2002-08-27 | Ludwig Institute For Cancer Research | Renal cancer associated antigens and uses therefor |
WO2001000874A2 (en) | 1999-06-30 | 2001-01-04 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
EP1261704B1 (en) | 1999-11-30 | 2009-07-01 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
AU2001229682A1 (en) * | 2000-01-21 | 2001-07-31 | Cornell Research Foundation Inc. | Small cell lung cancer associated antigens and uses therefor |
US6448073B1 (en) | 2000-01-28 | 2002-09-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
WO2002010357A2 (en) * | 2000-07-27 | 2002-02-07 | Chiron Corporation | Gsk3 polypeptides |
US20040086852A1 (en) * | 2000-12-01 | 2004-05-06 | Toshiro Ono | Cancer associated antigens and uses therefor |
US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
CN1313617C (zh) * | 2001-11-07 | 2007-05-02 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
JP2005529187A (ja) | 2002-06-13 | 2005-09-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 同種抗原の特定方法、ならびに癌治療および移植へのその使用 |
US8177823B2 (en) * | 2005-06-30 | 2012-05-15 | Depuy Spine Sarl | Orthopedic clamping hook assembly |
US8672732B2 (en) * | 2006-01-19 | 2014-03-18 | Schneider Electric It Corporation | Cooling system and method |
EP2046344A2 (en) * | 2006-07-14 | 2009-04-15 | MannKind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
ES2527412T3 (es) | 2007-02-15 | 2015-01-23 | Mannkind Corporation | Método para aumentar la respuesta de los linfocitos T |
WO2008148068A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
EP3192521B1 (en) | 2007-10-25 | 2020-09-16 | Toray Industries, Inc. | Immune response inducer |
AU2009270181B2 (en) | 2008-07-10 | 2014-05-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
KR101669827B1 (ko) | 2008-08-05 | 2016-10-27 | 도레이 카부시키가이샤 | 면역 유도제 |
RU2519089C2 (ru) * | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
EP2719774B8 (en) | 2008-11-07 | 2020-04-22 | Adaptive Biotechnologies Corporation | Methods of monitoring conditions by sequence analysis |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8691510B2 (en) * | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
DK3059337T3 (da) | 2009-01-15 | 2019-07-22 | Adaptive Biotechnologies Corp | Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier |
EA021100B1 (ru) | 2009-03-17 | 2015-04-30 | МДхХЭЛС СА | Усовершенствованное определение экспрессии генов |
KR20120044941A (ko) | 2009-06-25 | 2012-05-08 | 프레드 헛친슨 켄서 리서치 센터 | 적응 면역의 측정방법 |
AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
JP5923984B2 (ja) | 2010-02-04 | 2016-05-25 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
PL2532743T3 (pl) | 2010-02-04 | 2015-09-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka |
EP2711015B1 (en) | 2011-05-19 | 2016-06-29 | Toray Industries, Inc. | Immunity induction agent |
ES2595161T3 (es) | 2011-05-19 | 2016-12-28 | Toray Industries, Inc. | Agente inmunoinductor |
CA2844030C (en) | 2011-08-04 | 2019-09-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
HUE033628T2 (en) | 2011-08-04 | 2017-12-28 | Toray Industries | Method for detecting pancreatic cancer |
PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
CA2844034C (en) | 2011-08-04 | 2019-07-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
KR101979208B1 (ko) | 2011-08-04 | 2019-05-16 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US9279159B2 (en) | 2011-10-21 | 2016-03-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
EP3904536A1 (en) | 2011-12-09 | 2021-11-03 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
RU2632645C2 (ru) | 2012-02-21 | 2017-10-06 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
KR102005308B1 (ko) | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
IN2014KN01715A (ja) | 2012-02-21 | 2015-10-23 | Toray Industries | |
JP6187258B2 (ja) | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP2823060B1 (en) | 2012-03-05 | 2018-02-14 | Adaptive Biotechnologies Corporation | Determining paired immune receptor chains from frequency matched subunits |
DK2832366T3 (en) | 2012-03-30 | 2018-01-22 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer |
US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
JP5756247B1 (ja) | 2012-05-08 | 2015-07-29 | アダプティブ バイオテクノロジーズ コーポレイション | マルチプレックスpcr反応における増幅バイアスを測定し校正する組成物及び方法 |
US9753038B2 (en) | 2012-07-19 | 2017-09-05 | Toray Industries, Inc. | Method for detecting cancer via measurement of caprin-1 expression level |
TR201902972T4 (tr) | 2012-07-19 | 2019-03-21 | Toray Industries | Kanseri tespit etmek için yöntem. |
EP2904111B1 (en) | 2012-10-01 | 2017-12-06 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
US10150996B2 (en) | 2012-10-19 | 2018-12-11 | Adaptive Biotechnologies Corp. | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
JP6447130B2 (ja) | 2013-08-09 | 2019-01-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2015134787A2 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
WO2016069886A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corporation | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
KR20170141660A (ko) | 2015-04-30 | 2017-12-26 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
EP3290048B1 (en) | 2015-04-30 | 2020-09-23 | Toray Industries, Inc. | Immunity-inducing agent |
CN107604092A (zh) * | 2017-11-01 | 2018-01-19 | 中国医学科学院药用植物研究所 | 一种朝鲜淫羊藿与粗毛淫羊藿的分子鉴定方法 |
CN107619876A (zh) * | 2017-11-01 | 2018-01-23 | 中国医学科学院药用植物研究所 | 一种箭叶淫羊藿与天平山淫羊藿的分子鉴定方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583024A (en) * | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5274087A (en) * | 1986-08-13 | 1993-12-28 | Molecular Diagnostics, Inc. | cDNA coding for carcinoembryonic antigen (CEA) |
CA2079105C (en) * | 1990-04-04 | 2000-06-13 | Michael Houghton | Hepatitis c virus protease |
AT401180B (de) * | 1990-08-13 | 1996-07-25 | Biomay Biotech Prod | Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5405940A (en) * | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
US5585464A (en) * | 1993-02-19 | 1996-12-17 | Theratech, Inc. | Recombinant antigen for diagnosing rheumatoid arthritis |
ATE466869T1 (de) * | 1993-03-05 | 2010-05-15 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden |
FR2705362B1 (fr) * | 1993-05-18 | 1995-08-04 | Agronomique Inst Nat Rech | Clônage et expression du gêne de l'enzyme malolactique de Lactococcus lactis. |
EP0679716A4 (en) * | 1993-11-12 | 1999-06-09 | Kenichi Matsubara | GENE SIGNATURE. |
US5589579A (en) * | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
-
1995
- 1995-06-07 US US08/479,328 patent/US5698396A/en not_active Expired - Fee Related
-
1996
- 1996-06-07 AT AT00117699T patent/ATE235248T1/de not_active IP Right Cessation
- 1996-06-07 DK DK96919266T patent/DK0831879T3/da active
- 1996-06-07 AT AT96919266T patent/ATE222116T1/de active
- 1996-06-07 DE DE69627056T patent/DE69627056T2/de not_active Expired - Lifetime
- 1996-06-07 CA CA002223566A patent/CA2223566C/en not_active Expired - Lifetime
- 1996-06-07 ES ES96919266T patent/ES2180782T3/es not_active Expired - Lifetime
- 1996-06-07 PT PT96919266T patent/PT831879E/pt unknown
- 1996-06-07 WO PCT/US1996/009726 patent/WO1996040209A1/en active IP Right Grant
- 1996-06-07 JP JP50197297A patent/JP2002502354A/ja not_active Ceased
- 1996-06-07 EP EP96919266A patent/EP0831879B1/en not_active Expired - Lifetime
- 1996-06-07 DE DE69623014T patent/DE69623014T2/de not_active Expired - Lifetime
- 1996-06-07 CN CNB961956380A patent/CN1136914C/zh not_active Expired - Lifetime
- 1996-12-06 US US08/761,119 patent/US5798264A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2223566A1 (en) | 1996-12-19 |
US5698396A (en) | 1997-12-16 |
ATE222116T1 (de) | 2002-08-15 |
ES2180782T3 (es) | 2003-02-16 |
DE69627056D1 (de) | 2003-04-30 |
DK0831879T3 (da) | 2002-12-16 |
CA2223566C (en) | 2002-09-03 |
DE69623014D1 (de) | 2002-09-19 |
CN1190894A (zh) | 1998-08-19 |
WO1996040209A1 (en) | 1996-12-19 |
PT831879E (pt) | 2002-12-31 |
AU6165296A (en) | 1996-12-30 |
ATE235248T1 (de) | 2003-04-15 |
CN1136914C (zh) | 2004-02-04 |
EP0831879B1 (en) | 2002-08-14 |
US5798264A (en) | 1998-08-25 |
DE69627056T2 (de) | 2004-01-29 |
EP0831879A4 (en) | 2000-01-26 |
AU704109B2 (en) | 1999-04-15 |
EP0831879A1 (en) | 1998-04-01 |
DE69623014T2 (de) | 2003-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002502354A (ja) | 分子を同定又は単離する方法及びそれによって同定された分子 | |
US7524930B2 (en) | Tumor antigen | |
US6103873A (en) | Isolated renal cancer specific antigen | |
KR100384402B1 (ko) | 암 진단과 치료를 위한 방법과 정상 세포의 샘플에서병리적 마커를 확인하는 방법 | |
JP2002538074A (ja) | Ny−eso−1のアミノ酸配列に対応し、かつmhcクラスi分子及びmhcクラスii分子に結合する単離ペプチドおよびその利用方法 | |
WO2000050595A2 (en) | Nucleic acid molecules associated with melanoma and thyroid tumors | |
JP4097178B2 (ja) | 腫瘍抗原 | |
EP1108432B1 (en) | Method for identifying or isolating a molecule | |
JP2003533175A (ja) | Ny−eso−1ペプチド誘導体およびその使用 | |
JP2002531088A (ja) | 主要拒絶抗原 | |
US5864015A (en) | Hodgkin's disease associated molecules | |
US20050042624A1 (en) | Tumor antigen | |
AU704109C (en) | Method for identifying or isolating a molecule and molecules identified thereby |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060815 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070213 |